KLK3 and neoplasm: At environmentally relevant concentrations (1 nM), this agent is capable of activating the expression of prostate-specific antigen PSA, and inducing accelerated tumor growth in vivo, consequently facilitating the biochemical recurrence in tumors after therapy [42,43,44].